Modality
ERT
MOA
CDK4/6i
Target
PCSK9
Pathway
Autophagy
MM
Development Pipeline
Preclinical
~Jan 2016
→ ~Apr 2017
Phase 1
~Jul 2017
→ ~Oct 2018
Phase 2
~Jan 2019
→ ~Apr 2020
Phase 3
~Jul 2020
→ ~Oct 2021
NDA/BLA
Jan 2022
→ Apr 2030
NDA/BLACurrent
NCT06202382
331 pts·MM
2022-01→TBD·Completed
NCT04371085
984 pts·MM
2022-06→2030-04·Active
1,315 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-04-014.0y awayPh3 Readout· MM
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
NDA/BLA
Complet…
NDA/BLA
Active
Catalysts
Ph3 Readout
2030-04-01 · 4.0y away
MM
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06202382 | NDA/BLA | MM | Completed | 331 | ACR20 |
| NCT04371085 | NDA/BLA | MM | Active | 984 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R |